2242-31-1

Basic information

• Product Name: 1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYL-
• Synonyms: 1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYL-;N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-N-methylamine;1-(2,3-dihydro-1,4-benzodioxin-2-yl)-N-methylmethanamine;1-(2,3-dihydro-1,4-benzodioxin-2-yl)-N-methyl-methanamine;2,3-dihydro-1,4-benzodioxin-2-ylmethyl(methyl)amine;(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)methylamine(SALTDATA: HCl);N-(2,3-Dihydro-1,4-benzodioxin-2-ylMethyl)-n-MethylaMine, HCl;Methylaminomethylbenzodioxan
• CAS NO: 2242-31-1
• Molecular Formula: C₁₀H₁₃NO₂
• Molecular Weight: 179.22
• Mol File: 2242-31-1.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 261.2 °C at 760 mmHg
• Flash Point: 102 °C
• Appearance: /
• Density: 1.087 g/cm³
• Vapor Pressure: 0.0117mmHg at 25°C
• Refractive Index: 1.518
• CAS DataBase Reference: 1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYL-(2242-31-1)
• EPA Substance Registry System: 1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYL-(2242-31-1)

Safety Data

• Hazardous Substances Data: 2242-31-1(Hazardous Substances Data)

Usage

General Description

1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYL- is a chemical compound with the molecular formula C9H11NO2. It is a derivative of the benzodioxane structure and contains a methylamine group at the 2-position. 1,4-BENZODIOXAN-2-METHYLAMINE, N-METHYL- is used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and research chemicals. It may also have potential applications in the field of neuroscience and pharmacology due to its structural similarity to certain neurotransmitters and psychoactive compounds. Additionally, it is important to handle this chemical with caution as it may have various health and safety hazards associated with its handling and use.

InChI:InChI=1/C10H13NO2/c1-11-6-8-7-12-9-4-2-3-5-10(9)13-8/h2-5,8,11H,6-7H2,1H3

Upstream product

• 4442-59-5 (2,3-dihydrobenzo[1,4]dioxin-2-ylmethyl)amine 
• 21398-80-1 N-methyl-2,3-dihydrobenzo[b][1,4]dioxine-2-carboxamide 
• 2164-33-2 2-chloromethyl-1,4-benzodioxane 
• 74-89-5 methylamine 
• 4739-94-0 ethyl 2,3-dihydro-1,4-benzodioxin-2-carboxylate 
• 871824-54-3 N-((2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl)formamide 

Downstream Products

• 102128-83-6 N-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-N-methyl-β-alanine-methylamide 
• 102128-80-3 N-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-N-methyl-β-alanine-diethylamide 
• 102128-81-4 N-(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-N-methyl-β-alanine-dimethylamide 
• 73120-83-9 N-Methyl-N-(2-hydroxyethyl)(2,3-dihydro-1,4-benzodioxin-2-yl)methanamine 
• 114043-44-6 N-(Cyclohexyl-phenyl-methyl)-2-[(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amino]-acetamide 
• 119746-86-0 2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-{2-[(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amino]-ethyl} ester 5-methyl ester 
• 112358-09-5 2-amino>ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 
• 119746-87-1 2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-{2-[(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amino]-1-methyl-ethyl} ester 5-methyl ester 
• 119746-89-3 2,6-Dimethyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-{2-[(2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-methyl-amino]-ethyl} ester 5-isopropyl ester 
• 119746-93-9 1-Methyl-2-amino>ethyl isopropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate 

Relevant articles and documents

Novel, broad-spectrum anticonvulsants containing a sulfamide group: Pharmacological properties of (S)- N -[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2- yl)methyl]sulfamide (JNJ-26489112)

Broad-spectrum anticonvulsants are of considerable interest as antiepileptic drugs, especially because of their potential for treating refractory patients. Such "neurostabilizers" have also been used to treat other neurological disorders, including migraine, bipolar disorder, and neuropathic pain. We synthesized a series of sulfamide derivatives (4-9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity. Thus, we identified promising sulfamide 4 (JNJ-26489112) and explored its pharmacological properties. Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, electrically induced, and chemically induced seizures. Mechanistically, 4 inhibited voltage-gated Na+ channels and N-type Ca2+ channels and was effective as a K+ channel opener. The anticonvulsant profile of 4 suggests that it may be useful for treating multiple forms of epilepsy (generalized tonic-clonic, complex partial, absence seizures), including refractory (or pharmacoresistant) epilepsy, at dose levels that confer a good safety margin. On the basis of its pharmacology and other favorable characteristics, 4 was advanced into human clinical studies.

USE OF BENZO-FUSED HETEROCYCLE SULFAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN

The present invention is a method for the treatment of pain comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as desc

CO-THERAPY FOR THE TREATMENT OF EPILEPSY AND RELATED DISORDERS

The present invention is directed to co-therapy for the treatment of epilepsy and related disorders comprising administering to a subject in need thereof, co-therapy with a therapeutically effective amount of a benzo-fused heterocycle sulfamide derivative